Lalonde R, Lewis T L, Strazielle C, Kim H, Fukuchi K
Faculté de Médecine et de Pharmacie, Université de Rouen, 22 boulevard Gambetta, INSERM EMI 9906, IFRMP 23, Bâtiment de Recherche, Salle 1D18, 76183 Rouen Cedex, France.
Brain Res. 2003 Jul 4;977(1):38-45. doi: 10.1016/s0006-8993(03)02694-5.
The functional consequences of the betaAPP transgene with the Swedish mutation in mice were assessed in tests of exploratory activity and motor coordination. The betaAPP(695)SWE (Tg2576) transgenic mice are characterized by Abeta plaque formation in the neocortex and hippocampus. By comparison to non-transgenic mice controlled for age and gender, 17-month-old betaAPP(695)SWE transgenic mice displayed impaired spontaneous alternation, increased activity levels in the peripheral part of the open-field, and reduced anxiety in the elevated plus-maze. These results are similar to the loss of inhibitory control observed in some patients with Alzheimer's disease. These measures may be added to cognitive dysfunctions as testing ground for Abeta vaccination and other attempts at experimental therapies.
通过探索活动和运动协调性测试,评估了携带瑞典突变的β淀粉样前体蛋白(betaAPP)转基因小鼠的功能后果。β淀粉样前体蛋白(695)瑞典突变体(Tg2576)转基因小鼠的特征是在新皮层和海马体中形成β淀粉样蛋白斑。与按年龄和性别匹配的非转基因小鼠相比,17个月大的β淀粉样前体蛋白(695)瑞典突变体转基因小鼠表现出自发交替受损、旷场周边活动水平增加以及高架十字迷宫中焦虑减少。这些结果与在一些阿尔茨海默病患者中观察到的抑制控制丧失相似。这些指标可作为β淀粉样蛋白疫苗接种和其他实验性治疗尝试的测试对象,补充到认知功能障碍研究中。